Evaxion A/S has announced significant findings from its phase 2 trial of the personalized cancer vaccine EVX-01, indicating sustained clinical responses in patients with advanced melanoma. The three-year follow-up data shows that all patients maintained their clinical responses, with no tumor progression observed. This milestone is crucial as it reinforces the potential of personalized immunotherapies in treating cancer.
Evaxion A/S, a clinical-stage TechBio company, specializes in developing AI-Immunology™ powered vaccines. The company operates under the Standard Industrial Classification (SIC) code 2836, which covers biological products (no diagnostic substances). Evaxion trades on the Nasdaq under the ticker EVAX and is categorized as a non-accelerated filer and an emerging growth company.
The recent filing reveals that on October 19, 2026, Evaxion issued a press release detailing the results of its EVX-01 phase 2 trial. The report emphasizes that all patients at the three-year follow-up maintained clinical responses observed at the two-year mark, with no tumor progression noted. The data will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, from October 23-27.
According to the filing, the press release states, "We are highly excited by the new data reflecting a long durability of clinical responses in this hard-to-treat patient population." This statement underscores the company's optimism regarding the potential of EVX-01 as a viable treatment option for advanced melanoma.
The findings are expected to impact various stakeholders, including patients, healthcare providers, and investors in the biotech sector. The sustained clinical responses could enhance Evaxion's position in the competitive landscape of cancer immunotherapy, which includes other companies developing similar treatments.
Looking ahead, Evaxion will present its findings at the ESMO Congress and host a webinar on October 29, 2026, featuring key opinion leader and trial investigator Professor Muhammad Adnan Khattak. The webinar will provide further insights into the three-year clinical and immune data from the trial.